OptiNose, Inc. (OPTN)
Stock Price:
$3.78 USD
0.15 (4.13%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $3.65 -0.13 (-3.44%) Oct 22, 7:52 PM
Key Info
| Market Cap |
196.53M |
| Revenue (ttm) |
40.81M |
| Net Income (ttm) |
-108.51M |
| Shares Out |
51.99M |
| EPS (ttm) |
-2.46 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 22, 2020 |
| Last Price |
$3.78 |
| Previous Close |
$3.63 |
| Change ($) |
0.15 |
| Change (%) |
4.13% |
| Day's Open |
3.81 |
| Day's Range |
3.75 - 4.25 |
| Day's Volume |
666,715 |
| 52-Week Range |
3.28 - 11.66 |
More Stats
| Market Cap |
196.53M |
| Enterprise Value |
176.21M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
51.99M |
| Float |
30.38M |
| EPS (basic) |
-2.45 |
| EPS (diluted) |
-2.46 |
| FCF / Share |
-1.86 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6.93M |
| Short Ratio |
18.50 |
| Short % of Float |
22.82% |
| Beta |
0.78 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
4.82 |
| PB Ratio |
16.00 |
| Revenue |
40.81M |
| Operating Income |
-91.62M |
| Net Income |
-108.51M |
| Free Cash Flow |
-85.19M |
| Net Cash |
20.32M |
| Net Cash / Share |
0.39 |
| Gross Margin |
71.88% |
| Operating Margin |
-224.48% |
| Profit Margin |
-265.90% |
| FCF Margin |
-208.75% |
| ROA |
-35.83% |
| ROE |
-267.66% |
| ROIC |
-119.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$17.50*
(362.96% upside)
Low
13.0
Current: $3.78
High
20.0
Target: 17.50
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 34.63 | 7.07 | - | 47.50 | 0.09 |
| Revenue Growth | 390.18% | - | - | 55782.35% | - |
| Gross Profit | 29.34 | 5.48 | - | 47.50 | 0.09 |
| Operating Income | -95.60 | -100 | -48.53 | 25.32 | -28.08 |
| Net Income | -110 | -107 | -48.90 | 22.61 | -28.31 |
| Shares Outstanding | 41.88 | 39.77 | 11.00 | 4.05 | 4.05 |
| Earnings Per Share | -2.63 | -2.68 | -5.63 | 0.32 | -9.97 |
| Operating Cash Flow | -90.82 | -91.82 | -35.68 | 21.72 | -28.71 |
| Capital Expenditures | -0.56 | -1.69 | -2.41 | -0.22 | -0.08 |
| Free Cash Flow | -91.37 | -93.51 | -38.09 | 21.51 | -28.79 |
| Cash & Equivalents | 147 | 201 | 235 | 36.80 | 15.20 |
| Total Debt | 74.53 | 72.50 | 71.86 | 15.26 | 14.48 |
| Net Cash / Debt | 72.61 | 128 | 163 | 21.54 | 0.72 |
| Assets | 173 | 217 | 241 | 41.55 | 16.01 |
| Liabilities | 111 | 98.38 | 86.64 | 24.58 | 22.34 |
| Book Value | 61.58 | 119 | 154 | -151 | -161 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
OptiNose, Inc. |
| Country |
United States |
| Employees |
221 |
| CEO |
Peter Kaighn Miller |
Stock Information
| Ticker Symbol |
OPTN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: OPTN |
| IPO Date |
October 13, 2017 |
Description
OptiNose, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.